TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial to Determine the Efficacy and Safety of Coartemether and Artekin for the Treatment of Acute Falciparum and Vivax Malaria in Timika, Papua
Brief Summary: This open randomized, parallel group, 6 week trial in two rural outpatient clinics will compare the safety and efficacy of a six dose coartemether regimen with 3 dose artekin regimen for the treatment of acute, uncomplicated falciparum and vivax malaria in adults and children (\>10kg).


Options:
A: Intervention Type: DRUG; Name: amodiaquine+artesunate/artemether-lumefantrine; Assigned to Arm(s): N/A
B: Arm Label: Dihydroartemisin-piperaquine; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisin-piperaquine | Arm Label: Mefloquine + Artesunate (MAS3); Type: ACTIVE_COMPARATOR; Interventions: Drug: Mefloquine + Artesunate | Intervention Type: DRUG; Name: Dihydroartemisin-piperaquine; Assigned to Arm(s): Dihydroartemisin-piperaquine | Intervention Type: DRUG; Name: Mefloquine + Artesunate; Assigned to Arm(s): Mefloquine + Artesunate (MAS3)
C: Intervention Type: DRUG; Name: artesunate-amodiaquine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: coartem; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: artesunate-lapdap; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Artekin / Coartemther; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial to Determine the Efficacy and Safety of Coartemether and Artekin for the Treatment of Acute Falciparum and Vivax Malaria in Timika, Papua
Brief Summary: This open randomized, parallel group, 6 week trial in two rural outpatient clinics will compare the safety and efficacy of a six dose coartemether regimen with 3 dose artekin regimen for the treatment of acute, uncomplicated falciparum and vivax malaria in adults and children (\>10kg).


Options:
A: Intervention Type: DRUG; Name: Artekin / Coartemther; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin-piperaquine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine | Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Trimethoprim-sulfamethoxazole | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Dihydroartemisinin-piperaquine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Artemether-lumefantrine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Trimethoprim-sulfamethoxazole; Assigned to Arm(s): A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: amodiaquine-artesunate (ASAQ) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: dihydroartemisinin-piperaquine (DHAPQ) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: artemether-lumefantrine (AL) | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Lapdap (Chlorproguanil-Dapsone) + artesunate (AS) | Intervention Type: DRUG; Name: amodiaquine-artesunate (ASAQ); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine (DHAPQ); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: artemether-lumefantrine (AL); Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Lapdap (Chlorproguanil-Dapsone) + artesunate (AS); Assigned to Arm(s): 4
D: Arm Label: Dihydroartemisin-piperaquine; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisin-piperaquine | Arm Label: Mefloquine + Artesunate (MAS3); Type: ACTIVE_COMPARATOR; Interventions: Drug: Mefloquine + Artesunate | Intervention Type: DRUG; Name: Dihydroartemisin-piperaquine; Assigned to Arm(s): Dihydroartemisin-piperaquine | Intervention Type: DRUG; Name: Mefloquine + Artesunate; Assigned to Arm(s): Mefloquine + Artesunate (MAS3)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial to Determine the Efficacy and Safety of Coartemether and Artekin for the Treatment of Acute Falciparum and Vivax Malaria in Timika, Papua
Brief Summary: This open randomized, parallel group, 6 week trial in two rural outpatient clinics will compare the safety and efficacy of a six dose coartemether regimen with 3 dose artekin regimen for the treatment of acute, uncomplicated falciparum and vivax malaria in adults and children (\>10kg).


Options:
A: Arm Label: AM(LT); Type: ACTIVE_COMPARATOR; Interventions: Drug: AM(LT) | Arm Label: AM(FDC); Type: EXPERIMENTAL; Interventions: Drug: AM(FDC) | Arm Label: AL; Type: EXPERIMENTAL; Interventions: Drug: AL | Arm Label: DP; Type: EXPERIMENTAL; Interventions: Drug: DP | Arm Label: AA (FDC); Type: EXPERIMENTAL; Interventions: Drug: AA(FDC) | Intervention Type: DRUG; Name: AM(FDC); Assigned to Arm(s): AM(FDC) | Intervention Type: DRUG; Name: AM(LT); Assigned to Arm(s): AM(LT) | Intervention Type: DRUG; Name: AL; Assigned to Arm(s): AL | Intervention Type: DRUG; Name: DP; Assigned to Arm(s): DP | Intervention Type: DRUG; Name: AA(FDC); Assigned to Arm(s): AA (FDC)
B: Arm Label: pyronaridine artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine artesunate | Arm Label: chloroquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Intervention Type: DRUG; Name: Pyronaridine artesunate; Assigned to Arm(s): pyronaridine artesunate | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): chloroquine
C: Arm Label: Artekin; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin + Piperaquine (Artekin) | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: artesunate-sulphadoxin/pyrimethamine, chloroquine | Intervention Type: DRUG; Name: Dihydroartemisinin + Piperaquine (Artekin); Assigned to Arm(s): Artekin | Intervention Type: DRUG; Name: artesunate-sulphadoxin/pyrimethamine, chloroquine; Assigned to Arm(s): Standard treatment
D: Intervention Type: DRUG; Name: Artekin / Coartemther; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Consortium for Translation of Psychosocial Depression Theories to Interventions and Dissemination - Project 2: Phase I Randomized Controlled Trial of Patient Preference, Stepped-Care Treatment For Distress in Heart Disease Patients
Brief Summary: The specific aim of the "Coronary Patients Evaluation Study" (COPES) Project 2 is, within a Phase-I RCT, to examine patient satisfaction, treatment safety, and symptom reduction associated with treatment for symptoms of distress and/or depressed mood among post acute coronary syndrome (ACS) patients, as compared to usual cardiology care. For the purposes of this study, "symptoms of distress and/or depressed mood" is defined by a score on the Beck Depression Inventory (BDI) \>10. The specific treatment approach utilized follows the, "Improving Mood-Promoting Access to Collaborative Treatment" (IMPACT) Clinical Trial, and involves up to 6-months of a patient preference, stepped-care protocol. Within this protocol, patients choose between brief, problem focused psychotherapy and anti-depressant medication. Treatment progress is reviewed at 2-month intervals, providing opportunities to 'step-up' treatment if patients are not demonstrating sufficient symptom reduction.


Options:
A: Arm Label: Cohort 1; Type: N/A; Interventions: N/A | Arm Label: Cohort 2; Type: N/A; Interventions: N/A | Arm Label: Cohort 3; Type: N/A; Interventions: N/A | Arm Label: Cohort 4; Type: N/A; Interventions: N/A | Arm Label: Cohort 5; Type: N/A; Interventions: N/A
B: Arm Label: Intervention Condition (INT); Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced depression care | Arm Label: Usual Cardiologic Care Condition (UCC); Type: OTHER; Interventions: Behavioral: Referred depression care | Intervention Type: BEHAVIORAL; Name: Enhanced depression care; Assigned to Arm(s): Intervention Condition (INT) | Intervention Type: BEHAVIORAL; Name: Referred depression care; Assigned to Arm(s): Usual Cardiologic Care Condition (UCC)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy, Other: Usual cardiological care | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information session, Other: Usual cardiological care | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Information session; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Usual cardiological care; Assigned to Arm(s): 1, 2
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Home-based Metacognitive Therapy (Home-MCT) | Intervention Type: OTHER; Name: Home-based Metacognitive Therapy (Home-MCT); Assigned to Arm(s): Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Consortium for Translation of Psychosocial Depression Theories to Interventions and Dissemination - Project 2: Phase I Randomized Controlled Trial of Patient Preference, Stepped-Care Treatment For Distress in Heart Disease Patients
Brief Summary: The specific aim of the "Coronary Patients Evaluation Study" (COPES) Project 2 is, within a Phase-I RCT, to examine patient satisfaction, treatment safety, and symptom reduction associated with treatment for symptoms of distress and/or depressed mood among post acute coronary syndrome (ACS) patients, as compared to usual cardiology care. For the purposes of this study, "symptoms of distress and/or depressed mood" is defined by a score on the Beck Depression Inventory (BDI) \>10. The specific treatment approach utilized follows the, "Improving Mood-Promoting Access to Collaborative Treatment" (IMPACT) Clinical Trial, and involves up to 6-months of a patient preference, stepped-care protocol. Within this protocol, patients choose between brief, problem focused psychotherapy and anti-depressant medication. Treatment progress is reviewed at 2-month intervals, providing opportunities to 'step-up' treatment if patients are not demonstrating sufficient symptom reduction.


Options:
A: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Psycho edcuactional support; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducational support | Intervention Type: BEHAVIORAL; Name: Psychoeducational support; Assigned to Arm(s): Psycho edcuactional support
B: Arm Label: Collaborative Care; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative Care Treatment | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care Treatment | Intervention Type: BEHAVIORAL; Name: Collaborative Care Treatment; Assigned to Arm(s): Collaborative Care | Intervention Type: BEHAVIORAL; Name: Usual Care Treatment; Assigned to Arm(s): Usual Care
C: Arm Label: SMT-enhanced Cardiac Rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: SMT-enhanced Cardiac Rehabilitation | Arm Label: Standard Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Cardiac Rehabilitation | Intervention Type: BEHAVIORAL; Name: SMT-enhanced Cardiac Rehabilitation; Assigned to Arm(s): SMT-enhanced Cardiac Rehabilitation | Intervention Type: BEHAVIORAL; Name: Standard Cardiac Rehabilitation; Assigned to Arm(s): Standard Cardiac Rehabilitation
D: Arm Label: Intervention Condition (INT); Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced depression care | Arm Label: Usual Cardiologic Care Condition (UCC); Type: OTHER; Interventions: Behavioral: Referred depression care | Intervention Type: BEHAVIORAL; Name: Enhanced depression care; Assigned to Arm(s): Intervention Condition (INT) | Intervention Type: BEHAVIORAL; Name: Referred depression care; Assigned to Arm(s): Usual Cardiologic Care Condition (UCC)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Consortium for Translation of Psychosocial Depression Theories to Interventions and Dissemination - Project 2: Phase I Randomized Controlled Trial of Patient Preference, Stepped-Care Treatment For Distress in Heart Disease Patients
Brief Summary: The specific aim of the "Coronary Patients Evaluation Study" (COPES) Project 2 is, within a Phase-I RCT, to examine patient satisfaction, treatment safety, and symptom reduction associated with treatment for symptoms of distress and/or depressed mood among post acute coronary syndrome (ACS) patients, as compared to usual cardiology care. For the purposes of this study, "symptoms of distress and/or depressed mood" is defined by a score on the Beck Depression Inventory (BDI) \>10. The specific treatment approach utilized follows the, "Improving Mood-Promoting Access to Collaborative Treatment" (IMPACT) Clinical Trial, and involves up to 6-months of a patient preference, stepped-care protocol. Within this protocol, patients choose between brief, problem focused psychotherapy and anti-depressant medication. Treatment progress is reviewed at 2-month intervals, providing opportunities to 'step-up' treatment if patients are not demonstrating sufficient symptom reduction.


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Transtheoretical model-based (TTM - based) intervention and motivational interviewing (MI) | Intervention Type: OTHER; Name: Transtheoretical model-based (TTM - based) intervention and motivational interviewing (MI); Assigned to Arm(s): Intervention group
B: Arm Label: ACT-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: ACT-based intervention, Behavioral: usual care | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: ACT-based intervention; Assigned to Arm(s): ACT-based intervention | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): ACT-based intervention, Usual care
C: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega-3 Fatty Acid Supplement | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 Fatty Acid Supplement; Assigned to Arm(s): Treatment | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Intervention Condition (INT); Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced depression care | Arm Label: Usual Cardiologic Care Condition (UCC); Type: OTHER; Interventions: Behavioral: Referred depression care | Intervention Type: BEHAVIORAL; Name: Enhanced depression care; Assigned to Arm(s): Intervention Condition (INT) | Intervention Type: BEHAVIORAL; Name: Referred depression care; Assigned to Arm(s): Usual Cardiologic Care Condition (UCC)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pimozide Augmentation of Clozapine in Schizophrenia
Brief Summary: This study will assess the effectiveness of pimozide in enhancing the effects of clozapine in the treatment of schizophrenia.


Options:
A: Arm Label: Cariprazine 3mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Cariprazine 6mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Aripiprazole 10mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Cariprazine; Assigned to Arm(s): Cariprazine 3mg, Cariprazine 6mg | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole 10mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: pimozide; Type: EXPERIMENTAL; Interventions: Drug: Pimozide | Intervention Type: DRUG; Name: Pimozide; Assigned to Arm(s): pimozide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: sulpiride plus amisulpride; Type: EXPERIMENTAL; Interventions: Drug: full-dose amisulpride | Arm Label: full-dose amisulpride; Type: ACTIVE_COMPARATOR; Interventions: Drug: full-dose amisulpride | Intervention Type: DRUG; Name: full-dose amisulpride; Assigned to Arm(s): full-dose amisulpride, sulpiride plus amisulpride
D: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperdal | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Risperdal; Assigned to Arm(s): Active

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prophylaxis of Posttraumatic Stress Disorder With Post-Trauma Propranolol
Brief Summary: This study will assess the effectiveness of taking propranolol soon after a traumatizing incident in reducing the incidence and severity of posttraumatic stress disorder in acutely traumatized individuals.


Options:
A: Arm Label: Control Arm - Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Arm - Propranolol hydrochloride; Type: EXPERIMENTAL; Interventions: Drug: Propranolol Hydrochloride | Intervention Type: DRUG; Name: Propranolol Hydrochloride; Assigned to Arm(s): Intervention Arm - Propranolol hydrochloride
B: Arm Label: Oxepa; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Oxepa (enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding., Dietary Supplement: oxepa | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Control group | Intervention Type: DIETARY_SUPPLEMENT; Name: Oxepa (enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.; Assigned to Arm(s): Oxepa | Intervention Type: DIETARY_SUPPLEMENT; Name: oxepa; Assigned to Arm(s): Oxepa | Intervention Type: DIETARY_SUPPLEMENT; Name: Control group; Assigned to Arm(s): Control group
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Neuropeptide Y; Type: ACTIVE_COMPARATOR; Interventions: Drug: Neuropeptide Y | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Neuropeptide Y; Assigned to Arm(s): Neuropeptide Y | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Propranolol; Type: EXPERIMENTAL; Interventions: Drug: Propranolol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Propranolol; Assigned to Arm(s): Propranolol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Continuation Phase CBT for Youth With MDD
Brief Summary: This study will determine the effectiveness of cognitive behavioral therapy in preventing a relapse of depressive symptoms in children.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Multifamily Psychoeducation Group (MFPG), Behavioral: Treatment as usual (TAU) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Multifamily Psychoeducation Group (MFPG), Behavioral: Treatment as usual (TAU) | Intervention Type: BEHAVIORAL; Name: Multifamily Psychoeducation Group (MFPG); Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Treatment as usual (TAU); Assigned to Arm(s): 1, 2
B: Arm Label: Active, 1; Type: EXPERIMENTAL; Interventions: Drug: Sertraline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): Active, 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioral therapy (CBT), Drug: Drug therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Drug therapy | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Drug therapy; Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Drug: Citalopram | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Cognitive Behavioral Therapy (CBT), Drug: Citalopram | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine, Behavioral: Cognitive Behavioral Therapy (CBT) | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Venlafaxine; Assigned to Arm(s): 2, 4 | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): 3, 4 | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): 1, 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Continuation Phase CBT for Youth With MDD
Brief Summary: This study will determine the effectiveness of cognitive behavioral therapy in preventing a relapse of depressive symptoms in children.


Options:
A: Arm Label: Active, 1; Type: EXPERIMENTAL; Interventions: Drug: Sertraline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): Active, 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): Escitalopram | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Drug: Citalopram | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Cognitive Behavioral Therapy (CBT), Drug: Citalopram | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine, Behavioral: Cognitive Behavioral Therapy (CBT) | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Venlafaxine; Assigned to Arm(s): 2, 4 | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): 3, 4 | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): 1, 3
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioral therapy (CBT), Drug: Drug therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Drug therapy | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Drug therapy; Assigned to Arm(s): 1, 2

Answer: D